# FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OIVIB APPE	ROVAL
OMB Number:	3235-0287
Estimated average	burden
hours per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type	e Kesponses)														
	1. Name and Address of Reporting Person Chatterjee Saurav  (Last) (First) (Middle)  C/O AUGMEDIX, INC. 111 SUTTER  STREET, SUITE 1300  (Street)  SAN FRANCISCO, CA 94104		2. Issuer Name and Ticker or Trading Symbol Augmedix, Inc. [AUGX]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner						
C/O AUG			<b>~</b> ` ´	Date of Earliest Transaction (Month/Day/Year)     03/10/2022  4. If Amendment, Date Original Filed(Month/Day/Year)					X	X Officer (give title below) Other (specify below)  CHIEF TECHNOLOGY OFFICER  6. Individual or Joint/Group Filing(Check Applicable Line)  X_Form filed by One Reporting Person  Form filed by More than One Reporting Person					
SAN FRA									_X_ F						
(City)	(City) (State) (Zip)					Ta	ble I	- Non-Deriv	ative Securitie	s Acquired,	Disposed o	f, or Benefi	cially Owned		
1.Title of Sec (Instr. 3)				2A. Deemed Execution Date, if any (Month/Day/Year)  3. Tran Code (Instr. 5)		(A (In	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)  (A) or Amount (D) Price		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		C F D O	wnership orm: irect (D) Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Reminder: R	eport on a ser							in this fo	who respond orm are not re	quired to re	espond ur				1474 (9-02)
Reminder: R	oport on a seq		Table II					in this fo a curren ired, Dispos	orm are not re tly valid OMB ed of, or Benef	quired to re control nu icially Owne	espond ur mber.				474 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Table II and San Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code	tion	5. Number	r of (A)	in this for a currentired, Disposoptions, con 6. Date Exe Expiration I (Month/Day	orm are not re tly valid OMB ed of, or Benef vertible securit reisable and Date	quired to re control nu icially Owne	Amount	nless the f	orm displays  9. Number of	10. Ownersh Form of Derivativ Security Direct (I or Indire	11. Natur of Indirec Beneficia Ownershi (Instr. 4)
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transac Code	tion	5. Number Derivative Securities Acquired ( or Dispose (D) (Instr. 3, 4	r of (A)	in this for a currentired, Disposoptions, con 6. Date Exe Expiration I (Month/Day	orm are not re tly valid OMB  ed of, or Benef vertible securit rcisable and Date t/Year)  Expiration	control nu icially Owneries)  7. Title and of Underlying Securities	Amount	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	10. Ownersh Form of Derivativ Security Direct (I or Indire	ip of Indirec Beneficia Ownershi (Instr. 4)

		Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Chatterjee Saurav C/O AUGMEDIX, INC. 111 SUTTER STREET SUITE 1300 SAN FRANCISCO, CA 94104			CHIEF TECHNOLOGY OFFICER			

### **Signatures**

/s/ Todd Holvick, Attorney-in-Fact	03/11/2022
**Signature of Reporting Person	Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option is granted under the Augmedix, Inc. (the "Issuer") 2020 Equity Incentive Plan. The option will vest monthly in equal increments for four years starting on March 10, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date, and will be fully vested on March 10, 2026.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.